Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.

Hasse, B.; Walker, A.S.; Fehr, J.; Furrer, H.; Hoffmann, M.; Battegay, M.; Calmy, A.; Fellay, J.; Di Benedetto, C.; Weber, R.; Ledergerber, B.

doi:10.1128/AAC.01868-13

Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.

Details

Request a copy

Serval ID

serval:BIB_589B67538683

Type

Article: article from journal or magazin.

Collection

Publications

Institution

UNIL/CHUV

Title

Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.

Journal

Antimicrobial Agents and Chemotherapy

Author(s)

Hasse B., Walker A.S., Fehr J., Furrer H., Hoffmann M., Battegay M., Calmy A., Fellay J., Di Benedetto C., Weber R., Ledergerber B.

Working group(s)

Swiss HIV Cohort Study

Contributor(s)

Aubert V., Barth J., Battegay M., Bernasconi E., Böni J., Bucher HC., Burton-Jeangros C., Calmy A., Cavassini M., Egger M., Elzi L., Fehr J., Fellay J., Francioli P., Furrer H., Fux CA., Gorgievski M., Günthard H., Haerry D., Hasse B., Hirsch HH., Hirschel B., Hösli I., Kahlert C., Kaiser L., Keiser O., Kind C., Klimkait T., Kovari H., Ledergerber B., Martinetti G., Martinez de Tejada B., Metzner K., Müller N., Nadal D., Pantaleo G., Rauch A., Regenass S., Rickenbach M., Rudin C., Schmid P., Schultze D., Schöni-Affolter F., Schüpbach J., Speck R., Taffé P., Tarr P., Telenti A., Trkola A., Vernazza P., Weber R., Yerly S.

ISSN

1098-6596 (Electronic)

ISSN-L

0066-4804

Publication state

Published

Issued date

2014

Peer-reviewed

Oui

Volume

Number

Pages

2363-2368

Language

english

Notes

Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish

Abstract

Co-trimoxazole reduces mortality in HIV-infected adults with tuberculosis (TB), and in vitro data suggest potential antimycobacterial activity of co-trimoxazole. We aimed to evaluate whether prophylaxis with co-trimoxazole is associated with a decreased risk of incident TB in Swiss HIV Cohort Study (SHCS) participants. We determined the incidence of TB per 1,000 person-years from January 1992 to December 2012. Rates were analyzed separately in participants with current or no previous antiretroviral treatment (ART) using Poisson regression adjusted for CD4 cell count, sex, region of origin, injection drug use, and age. A total of 13,431 cohort participants contributed 107,549 person-years of follow-up: 182 patients had incident TB-132 (73%) before and 50 (27%) after ART initiation. The multivariable incidence rate ratios for cumulative co-trimoxazole exposure per year for persons with no previous ART and current ART were 0.70 (95% confidence interval [CI], 0.55 to 0.89) and 0.87 (95% CI, 0.74 to 1.0), respectively. Co-trimoxazole may prevent the development of TB among HIV-positive persons, especially among those with no previous ART.

OAI-PMH

oai:serval.unil.ch:BIB_589B67538683

DOI

10.1128/AAC.01868-13

Pubmed

24514096

Web of science

000333605600065

Open Access

Yes

Create date

01/05/2014 18:50